Video Endoscopic Sequence 3 of 3
Reconstitute in sterile water or appropriate buffered aqueous solution depending on assay requirements
To assess the association of semaglutide with incident CUD, the study population included 587,849 patients with T2D who had active medical encounters for T2D during 12/20175/2021, were for the first time prescribed semaglutide (Ozempic) or non-GLP1-1RA anti-diabetes medications (new-user design) during 12/20175/2021(index event), had no diagnosis of CUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
Advantages of secretagogues in research: a more physiological hormonal profile, activation of the complete axis (GH + IGF-1 + IGFBP-3), and intact negative feedback that limits supraphysiological effects
Semaglutide, the active ingredient in Wegovy, produces dose-dependent weight loss
![PDF] Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models](https://figures.semanticscholar.org/d83a64f6b7193358c31030487761fc19c80dd33c/3-Figure1-1.png)
